Neurocrine Biosciences (NBIX) to Release Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) will post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Neurocrine Biosciences to post earnings of $1.04 per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm's quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.88 EPS. On average, analysts expect Neurocrine Biosciences to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX traded down $1.12 on Wednesday, reaching $138.97. The stock had a trading volume of 927,988 shares, compared to its average volume of 850,986. The stock has a market cap of $13.83 billion, a P/E ratio of 57.43 and a beta of 0.25. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $148.37. The business's 50-day moving average price is $136.48 and its 200 day moving average price is $127.62.

Analyst Upgrades and Downgrades

Several research firms recently commented on NBIX. Wedbush reiterated an "outperform" rating and issued a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a report on Tuesday. Barclays raised their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a report on Tuesday, January 23rd. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an "overweight" rating in a research report on Wednesday, March 20th. Finally, StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $142.38.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the transaction, the director now directly owns 29,512 shares of the company's stock, valued at $3,909,454.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Richard F. Pops sold 15,000 shares of the business's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the sale, the director now directly owns 29,512 shares in the company, valued at approximately $3,909,454.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Benevich sold 19,818 shares of the firm's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now owns 40,778 shares of the company's stock, valued at $5,438,154.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 186,994 shares of company stock valued at $25,806,409. Corporate insiders own 4.60% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.